ClinConnect ClinConnect Logo
Search / Trial NCT06775275

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Jan 9, 2025

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with resectable non-small cell lung cancer (NSCLC), which is a type of lung cancer that can still be surgically removed. Researchers want to see how effective and safe a combination of a medication called adebrelimab with chemotherapy (and possibly another drug called bevacizumab) is for this condition. The trial is open to adults aged 18 to 65 who have not yet received any prior treatment for their cancer and have a good level of health.

If you or someone you know is considering participating in this trial, you should be aware that participants will receive the study treatment and will be monitored closely for any side effects. To be eligible, patients must have a specific type of lung cancer that can be operated on and must meet certain health criteria, including having enough lung function for surgery. It’s important to note that patients with other types of lung cancer or those who have previously received certain cancer treatments may not qualify to participate. This trial is currently recruiting participants, and being part of it could help researchers learn more about effective treatments for lung cancer.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Resectable NSQ NSCLC
  • Age 18-65 years
  • male or female
  • ECOG 0-1
  • Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
  • Subjects must have adequate pulmonary function for the intended pneumonectomy;
  • Exclusion Criteria:
  • SCLC or SQ NSCLC
  • previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
  • patients who have previously used anti-angiogenic drugs;
  • allergic to any component of the study drug or chemotherapy drugs
  • patients with any severe and or uncontrolled disease

About The First Affiliated Hospital Of Guangzhou Medical University

The First Affiliated Hospital of Guangzhou Medical University is a leading clinical research institution located in Guangzhou, China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative research. As a comprehensive teaching hospital, it integrates clinical practice, education, and research, fostering a multidisciplinary approach to healthcare. The hospital is equipped with state-of-the-art facilities and a team of experienced professionals dedicated to conducting high-quality clinical trials across various therapeutic areas. By leveraging its extensive expertise and resources, the First Affiliated Hospital aims to contribute significantly to the development of new treatments and therapies, enhancing health outcomes for patients both locally and globally.

Locations

Guangzhou, , China

Patients applied

0 patients applied

Trial Officials

Jianxing He

Principal Investigator

The First Affiliated Hospital of Guangzhou Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported